Analysts predict that OvaScience Inc (NASDAQ:OVAS) will report sales of $80,000.00 for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for OvaScience’s earnings, with the lowest sales estimate coming in at $60,000.00 and the highest estimate coming in at $100,000.00. OvaScience posted sales of $120,000.00 in the same quarter last year, which would indicate a negative year-over-year growth rate of 33.3%. The company is expected to issue its next quarterly earnings report on Thursday, March 1st.
According to Zacks, analysts expect that OvaScience will report full-year sales of $80,000.00 for the current year, with estimates ranging from $260,000.00 to $300,000.00. For the next financial year, analysts forecast that the company will report sales of $2.01 million per share, with estimates ranging from $220,000.00 to $5.52 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for OvaScience.
Several equities analysts have commented on the company. Zacks Investment Research downgraded OvaScience from a “buy” rating to a “hold” rating in a research report on Thursday, January 11th. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of OvaScience in a research report on Monday, November 6th.
Institutional investors and hedge funds have recently modified their holdings of the company. Susquehanna International Group LLP raised its position in shares of OvaScience by 87.2% during the second quarter. Susquehanna International Group LLP now owns 112,781 shares of the biotechnology company’s stock worth $176,000 after acquiring an additional 52,538 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of OvaScience by 28.8% during the second quarter. Wells Fargo & Company MN now owns 164,283 shares of the biotechnology company’s stock worth $256,000 after acquiring an additional 36,720 shares during the last quarter. Two Sigma Investments LP bought a new position in shares of OvaScience during the fourth quarter worth about $342,000. Broadfin Capital LLC bought a new position in shares of OvaScience during the second quarter worth about $429,000. Finally, Deutsche Bank AG raised its position in shares of OvaScience by 7,476.4% during the fourth quarter. Deutsche Bank AG now owns 517,693 shares of the biotechnology company’s stock worth $724,000 after acquiring an additional 510,860 shares during the last quarter. Institutional investors own 54.88% of the company’s stock.
OvaScience (OVAS) traded down $0.04 during trading on Friday, reaching $0.98. The company’s stock had a trading volume of 476,500 shares, compared to its average volume of 876,074. OvaScience has a 1 year low of $0.90 and a 1 year high of $2.05.
ILLEGAL ACTIVITY WARNING: This news story was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/02/14/80000-00-in-sales-expected-for-ovascience-inc-ovas-this-quarter.html.
OvaScience Company Profile
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
Get a free copy of the Zacks research report on OvaScience (OVAS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.